Stent

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Retrieved on: 
Monday, November 27, 2023

As a result, there are currently no FDA approved stents for this specific indication.

Key Points: 
  • As a result, there are currently no FDA approved stents for this specific indication.
  • Retrospective analyses from large centers across the globe have suggested the safety and efficacy of stenting in conjunction with intracranial thrombectomy.
  • I am also excited that this brings the carotid disease as it pertains to neurointerventionalists to the forefront.
  • The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.

EQS-News: Bentley Endovascular Group AB paves the way for the new Bentley Campus by tripling size of its German location

Retrieved on: 
Thursday, December 21, 2023

Bentley CEO Sebastian Büchert and the Strobel family, owners of Best Freizeitmoebel GmbH, signed the corresponding agreement today.

Key Points: 
  • Bentley CEO Sebastian Büchert and the Strobel family, owners of Best Freizeitmoebel GmbH, signed the corresponding agreement today.
  • The previous owner, Best, will gradually hand over the use of the site to Bentley until the middle of 2025.
  • The old production buildings and warehouses on the Best site will therefore make way for the new Bentley Campus in the years to come.
  • Image subtitle: Bentley paves the way for the new Bentley Campus by tripling the size of its Hechingen Lotzenäcker location (in blue, the existing Bentley premises, marked in red the properties purchased from BEST)

Global Drug Eluting Stent Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023

The "Drug Eluting Stent Market Size, Share & Trends Analysis Report By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Eluting Stent Market Size, Share & Trends Analysis Report By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global drug eluting stent market size is expected to reach USD 13.65 billion by 2030, advancing at a CAGR of 8.4%
    An aging population and the increasing prevalence of risk factors such as cardiovascular diseases (CVDs), complex lesions, diabetes, obesity, and others are expected to drive the demand for drug eluting stents over the forecast period.
  • Additionally, ongoing technological advancements in stent design, including improvements in coatings and drug delivery mechanisms, are enhancing the safety and efficacy of these devices, making them more appealing to patients and healthcare professionals.
  • The market for drug eluting stents was significantly impacted by the COVID-19 pandemic, with disruptions in the supply chain of medical devices.

Bioresorbable Stents Global Strategic Market Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 15, 2023

The "Bioresorbable Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioresorbable Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Bioresorbable Stents estimated at US$390.2 Million in the year 2022, is projected to reach a revised size of US$990.5 Million by 2030, growing at a CAGR of 12.4% over the analysis period 2022-2030.
  • The report delves into the overall market analysis, covering the period from 2020 to 2030, offering valuable insights for stakeholders in the bioresorbable stents industry.
  • This report also presents a comprehensive analysis of the global bioresorbable stents market, focusing on Europe, Asia-Pacific, and the Rest of the World regions.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery

Retrieved on: 
Thursday, November 2, 2023

CHATTANOOGA, Tenn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Occlusion Perfusion Catheter (OPC), a multi-lumen balloon catheter from Advanced Catheter Therapies (ACT), was recently selected by researchers for use in exploring a new treatment approach for peripheral artery disease (PAD) and restenosis.

Key Points: 
  • CHATTANOOGA, Tenn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Occlusion Perfusion Catheter (OPC), a multi-lumen balloon catheter from Advanced Catheter Therapies (ACT), was recently selected by researchers for use in exploring a new treatment approach for peripheral artery disease (PAD) and restenosis.
  • Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of PAD.
  • To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form.
  • “ Pre-clinical investigation of liquid sirolimus for local drug delivery ” was published September 15, 2023, in Frontiers in Cardiovascular Medicine .

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Retrieved on: 
Wednesday, November 1, 2023

The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIANS trial.

Key Points: 
  • The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIANS trial.
  • From July 2021 to June 2023, 316 patients were prospectively enrolled in this single-arm carotid artery stenting study performed at 24 sites in the US and the EU.
  • Stenting with the C-Guard carotid stent system in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, from procedure through 30 days follow-up.
  • We believe the neuroprotective qualities of C-Guard set it apart from competing stents on the market and should help accelerate the ongoing shift in carotid revascularizations from ‘surgery first’ to an endovascular ‘stent first’ approach.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

EQS-News: Bentley Endovascular Group AB brings on-board Keensight Capital, A.P. Moller Holding, and Bonit Capital as new investors

Retrieved on: 
Friday, October 27, 2023

Bentley Endovascular Group AB brings on-board Keensight Capital,

Key Points: 
  • Bentley Endovascular Group AB brings on-board Keensight Capital,
    Keensight Capital (“Keensight”) invests in Bentley Endovascular Group AB (“Bentley” or “the Group”) alongside A.P.
  • The founders and management retain control and still hold the majority of the capital and the votes in the Swedish holding company Bentley Endovascular Group AB.
  • Headquartered in Stockholm, Sweden, Bentley Endovascular Group AB controls its key subsidiary Bentley InnoMed GmbH and Qmedics AG.
  • Bentley Endovascular Group AB: Stent production at the major site in Hechingen, Germany
    Bentley Endovascular Group AB: Major production site at Hechingen, Germany